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Abstract
The objective of this study was to observe possible interactions between the renin-angiotensin and nitrergic systems in chronic 
hypoxia-induced pulmonary hypertension in newborn piglets. Thirteen chronically instrumented newborn piglets (6.3 ± 0.9 days; 
2369 ± 491 g) were randomly assigned to receive saline (placebo, P) or the AT1 receptor (AT1-R) blocker L-158,809 (L) during 
6 days of hypoxia (FiO2 = 0.12). During hypoxia, pulmonary arterial pressure (Ppa; P < 0.0001), pulmonary vascular resistance 
(PVR; P < 0.02) and the pulmonary to systemic vascular resistance ratio (PVR/SVR; P < 0.05) were significantly attenuated in 
the L (N = 7) group compared to the P group (N = 6). Western blot analysis of lung proteins showed a significant decrease of 
endothelial NOS (eNOS) in both P and L animals, and of AT1-R in P animals during hypoxia compared to normoxic animals (C 
group, N = 5; P < 0.01 for all groups). AT1-R tended to decrease in L animals. Inducible NOS (iNOS) did not differ among P, L, 
and C animals and iNOS immunohistochemical staining in macrophages was significantly more intense in L than in P animals 
(P < 0.01). The vascular endothelium showed moderate or strong eNOS and AT1-R staining. Macrophages and pneumocytes 
showed moderate or strong iNOS and AT1-R staining, but C animals showed weak iNOS and AT1-R staining. Macrophages 
of L and P animals showed moderate and weak AT2-R staining, respectively, but the endothelium of all groups only showed 
weak staining. In conclusion, pulmonary hypertension induced by chronic hypoxia in newborn piglets is partially attenuated by 
AT1-R blockade. We suggest that AT1-R blockade might act through AT2-R and/or Mas receptors and the nitrergic system in 
the lungs of hypoxemic newborn piglets.
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Pulmonary hypertension induced by chronic hypoxia is a 
complex process of sustained elevation of pulmonary artery 
pressure involving vasoconstriction and pulmonary vessel 
remodeling. These events have been consistently observed 
in experimental animal models and in adult humans (1), but 
in newborns and in neonatal animal models, only one study 
showed involvement of the renin-angiotensin system (RAS) 
(2). They are multifactorial processes involving different 
mediators such as endothelin and angiotensin II (Ang II) and 
nitric oxide. Ang II is a powerful pulmonary vasoconstric-
tor and promoter of vascular smooth muscle cell (VSMC) 
growth in humans and animals. Ang II can act through the 
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angiotensin type 1 receptor (AT1-R) to induce mitogenesis, 
stimulate DNA synthesis, promote cellular proliferation in 
cultured rat VSMC, and to enhance growth factors such 
as platelet-derived growth factor and transforming-growth 
factor β (3-5). The mechanisms of action of Ang II involve 
binding to AT1-R, as demonstrated in different studies 
reporting attenuation of pulmonary hypertension by AT1-R 
blockers and transient up-regulation of AT1-R in adult rats 
exposed to chronic hypoxia (6,7). Moreover, we have dem-
onstrated that pulmonary vasoconstriction induced by acute 
hypoxia was significantly attenuated by the AT1-R blocker 
losartan in piglets (2). Therefore, it is possible that the 
RAS participates in the mechanisms leading to pulmonary 
hypertension induced by chronic hypoxia (4,5). 
It is well known that AT1-R blockade stimulates nitric 
oxide (NO) production via AT2-R, a process that may result 
in the attenuation of pulmonary hypertension induced by 
chronic hypoxia (8,9). One possible endothelial mecha-
nism of regulation of the pulmonary vascular tone during 
chronic hypoxia is by decreasing endothelial NO synthase 
(eNOS) expression, a hypothesis supported by the fact 
that eNOS expression is significantly lower in newborn 
piglets exposed to chronic hypoxia compared to a control 
group (10). However, the interactions between the RAS and 
nitrergic systems in the pulmonary vasculature have not 
been studied in human or animal newborns with pulmonary 
hypertension induced by chronic hypoxia. Asphyxiated 
newborn infants are predisposed to persistent pulmonary 
hypertension, and these mechanisms could be partially 
involved in this condition (11).
We propose, as a working hypothesis, that pulmonary 
hypertension induced by chronic hypoxia in newborn piglets 
is mediated by increased circulating Ang II levels, associ-
ated with down-regulation of eNOS. As a consequence, 
hypoxic pulmonary hypertension can be ameliorated by 
pretreatment with the AT1-R blocker L-158,809 through 
increased NO production.
Material and Methods 
Animal preparation
Thirteen newborn piglets (age = 6.3 ± 0.9 days; weight = 
2369 ± 491 g) were anesthetized intraperitoneally (ip), with 
2% (w/v) isoflurane and 50 µg/kg fentanyl. The piglets were 
paralyzed with an ip injection of 0.4 mg/kg pancuronium 
bromide. A 3.5-mm tube was placed in the trachea and 
the piglet was mechanically ventilated with a time-cycled, 
pressure-limited infant ventilator (Sechrist, Model IV-100 B 
Infant Ventilator, USA) with peak inspiratory pressure set at 
12 cmH2O, positive end-expiratory pressure set at 2 cmH2O, 
with a respiratory rate of 30 breaths/min, an inspiratory time 
of 0.5 s, and FiO2 = 0.50 during surgery. The femoral artery 
was cannulated with a 3.5-French umbilical catheter and 
the femoral vein with a 5-French Swan-Ganz thermodilution 
catheter. The Swan-Ganz catheter was advanced under 
fluoroscopic guidance into the pulmonary artery, and was 
maintained patent with a heparin lock (1000 U/mL). Both 
catheters were fixed in a pouch located on the back of the 
animal. The piglets received cefoxitin intravenously at 100 
mg·kg-1·day-1 and acetaminophen (10 mg/kg orally) im-
mediately after surgery and thereafter as needed.
The femoral artery catheter was used for mean systemic 
arterial pressure (Psa) measurements and for blood sam-
pling for the determination of arterial blood gases (ABG), 
pH, and hemoglobin. The Swan-Ganz catheter was used 
to measure pulmonary artery (Ppa) and wedge pressure 
(Pwp), right atrial pressure (Rap), and cardiac output (CO). 
CO was measured by thermodilution using a CO computer 
(Model 95510-1, Edwards Laboratory, USA). Vascular pres-
sures (Ppa, Pwp, Rap, Psa) were measured with pressure 
transducers (Model P23-ID, Gould Instruments, USA) and 
Grass pre-amplifiers (Model 7D, Grass Instrument, USA). 
All signals were simultaneously digitized with a frequency 
of 100 Hz using an analog-to-digital board (AT - CODAS, 
Dataq Instruments Inc., USA) and stored in a personal 
computer for analysis. ABG and pH were analyzed with a 
blood gas analyzer (model 238, Ciba-Corning, England) 
and corrected for core temperature. Hemoglobin was 
measured with a CO-oximeter (model 482 - Instrumenta-
tion Laboratory, USA).
Study protocol 
The studies were started 48-72 h after surgery. Thirteen 
unanesthetized and chronically instrumented newborn pig-
lets were randomly assigned to receive saline as placebo (P 
group; N = 6), or the AT1-R antagonist L-158,809 (L group; 
N = 7). The animals were placed in a sling inside a Plexiglas 
chamber, in a thermoneutral environment (26°-28°C) with 
70% relative humidity, where CO2 was scavenged with soda 
lime, and the CO2 tension was kept at less than 6 mmHg. 
Piglets were fed ad libitum with newborn piglet milk during 
the study. All hemodynamic measurements were made dur-
ing quiet sleep and evaluated by behavioral assessment. 
Heparinized saline was infused continuously through the 
pulmonary artery catheter (10 IU/mL) at a rate of 5 mL/h 
throughout the study. 
After a 30-min period of stabilization, the hemodynamic 
measurements (Psa, Ppa, Pwp, Rap, CO), and blood sam-
pling for ABG were obtained and referred to as baseline 
normoxia values. Saline or L-158,809 (1 mg·kg-1·day-1, ip) 
was administered to the animals immediately after the mea-
surements. The potassium salt of L-158,809 was prepared 
at 3 mg/mL in 15% (w/v) saturated sodium bicarbonate 
solution and the dose was selected on the basis of a study 
performed in adult pigs (12). After obtaining the baseline 
values, the oxygen concentration was reduced to 12% and 
kept at this level for 6 days, allowing free movement of 
the animals. The hemodynamic measurements and blood 
sampling were repeated twice on the second and sixth 
days of continuous hypoxia. Systemic vascular (SVR) and 
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pulmonary vascular (PVR) resistances were calculated 
from the hemodynamic data. Five healthy newborn piglets 
were used as controls for immunohistochemistry and for 
immunoblotting studies (C group).
Handling and care of the animals were in accordance 
with the guidelines of the National Institute of Health, and 
the study protocol was approved by the Animal Care and 
Use Committee of the University of Miami.
Pathology and immunohistochemistry
Piglets were sacrificed with Euthanasia® solution im-
mediately after completion of the experiment and the lungs 
were removed en bloc from the thorax. One lung was inflated 
through the trachea with 4% (w/v) paraformaldehyde in 0.1 
M sodium phosphate buffer, pH 7.4, at room temperature, 
using a column pressure of 20 cmH2O for 30 min, and was 
then immersion-fixed in the same solution for at least 1 week. 
The other lung was processed for paraffin embedding.
The fixed lung was dehydrated, cleared with xylene and 
paraffin-embedded. Five-micrometer sections were cut, 
mounted on gelatin-chromalum-coated glass slides, and 
used for immunohistochemistry. All sections from groups C, 
P, and L were immunostained simultaneously for each of the 
primary antibodies used. Antigen recovery from dewaxed 
lung sections was carried out using a microwave oven, and 
immunostaining was performed as described elsewhere 
(13,14). Sections were then incubated with rabbit anti-
AT1-R (Santa Cruz Biotechnology Inc., USA), goat anti-AT2 
(Santa Cruz Biotechnology), mouse anti-eNOS (clone 3, BD 
Transduction Laboratories, USA), mouse anti-iNOS (clone 
6, BD Transduction Laboratories), or rabbit anti-smooth 
muscle anti-α-actin (RDI Inc., USA) antibodies. Controls 
were prepared by incubating sections overnight with anti-
AT1-R or anti-AT2-R antibodies previously adsorbed with 
their respective immunogens at 1:10 (w/v) and 1:5 (w/v) in 
blocking buffer, respectively. Primary antibodies replaced 
blocking buffer in additional controls. Antibodies were de-
tected with a secondary biotinylated antibody and the Elite 
ABC kit (Vector, USA), using 3,3’-diaminobenzidine (Pierce 
Biotechnology Inc., USA) as the chromogen. Sections were 
analyzed and photographed with a model BX60-F3 micro-
scope, a PM-35DX camera and a PM30 exposure control 
module (Olympus, Japan). Images were digitized using 
a Sprintscan 35 Plus Polaroid, and plates were mounted 
using the Photoshop 7.0 software.
Immunohistochemically stained sections were evaluated 
and scored blindly and independently by two investigators 
(ARM, SGR). A numerical value (modal score) ranging from 
0 to 3 was assigned by each investigator to each slide on 
the basis of intensity and distribution of the stain, for the 
following variables: arterial and venular endothelium, cap-
illaries, macrophages, alveolar interstitium, alveolar cells 
(type I and II pneumocytes), and bronchial epithelium. A 
zero score was assigned if no stain was present, grade 1 
was assigned if there was mild staining, grade 2 if there 
was moderate staining, and grade 3 if staining was strong 
(15,16).
Western blotting analysis
Frozen lungs were homogenized (1 g lung to 9 mL buf-
fer) in a water-ice bath, in 20 mM Tris-HCl buffer, pH 7.4, 
containing 0.32 M sucrose, 1% (w/v) sodium dodecyl sulfate 
(SDS), 10 mM disodium ethylenediamine tetra-acetic acid, 
1 mM benzamidine, 0.3 mM phenylmethanesulfonylfluoride, 
0.3 µM aprotinine, and 2 mM β-mercaptoethanol, using a 
Potter-Elvehjem homogenizer (Glas-Col, USA) at 1000 
rpm. Homogenates were subjected to SDS-PAGE in 7-20% 
gradient gels using a discontinuous system (17). Proteins 
on the gel were transferred to nitrocellulose membranes 
(Hybond ECL, Amersham Biosciences, England) (18), which 
were used for the immunodetection of eNOS, inducible NOS 
(iNOS) and AT1-R, using the same primary antibodies as 
those employed for immunohistochemistry. Immunoblots 
were developed and documented using an enhanced chemi-
luminescence kit (Amersham Biosciences) and Hyperfilm 
ECL (Amersham Biosciences), respectively. Controls were 
obtained using primary antibodies pre-adsorbed with their 
respective immunogens, and also omitting the primary an-
tibodies. Immunoblotting images were quantified using the 
Gel-Pro Analyzer version 3.1 software (Media Cybernetics, 
USA). Integrated optical densities (IOD) for the specific 
protein bands were determined, and the ratio IOD/µg ho-
mogenate protein applied to the gel was calculated.
Statistical analyses
Repeated measures analysis of variance (ANOVA) was 
used to compare the hemodynamic patterns of response of 
the P and L groups, both over time (time-treatment interac-
tion) and independent of time (overall group difference) for 
the dependent variables. One-way ANOVA was used to 
compare Western blot data among the P, L, and C groups, 
and the Tukey multiple comparison test was used as post 
hoc analysis. The Mann-Whitney rank sum test was used to 
compare the immunohistochemical scores. The consistency 
between two investigators scoring immunohistochemical 
results was analyzed using the weighed κ coefficient that 
ranged from 0.7 to 0.85, thus indicating good agreement. 
Data are reported as means ± SD. P < 0.05 was considered 
to be statistically significant.
Results
There were no statistically significant differences in 
weight gain or hemoglobin between the P and L groups at 
any time in room air or 12% O2. There were no significant 
differences in ABG or acid-base values in room air/normoxia 
and hypoxia or in systemic hemodynamic responses (Psa, 
SVR, and CO) between the P and L groups. There was a 
statistically significant difference from normoxia to hypoxia 
in PaO2 values in both groups (Table 1). A significant attenu-
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ation of Ppa (P < 0.0001) and PVR (P < 0.02), and a de-
crease in the PVR/SVR ratio were observed during chronic 
hypoxia after AT1 receptor blockade (Figure 1), suggesting 
a selective action on the pulmonary circulation. 
Immunohistochemistry 
The endothelium of blood vessels with a diameter up to 
600 µm exhibited a moderate (groups L and P; Figure 2A 
and B, respectively) or strong (control; Figure 2C) staining 
by anti-eNOS antibody. However, modal scores for eNOS 
staining were not significantly different among the three 
groups (Table 2).
The endothelium of the pulmonary arteries of the L and 
P groups was weakly stained (grade 1; Figure 2D,E) 
Figure 1. A, Pulmonary artery pressure (Ppa); B, pulmonary vascular resistance (PVR), and C, PVR/SVR ratio in normoxia and on 
the second and sixth days of hypoxia in the P and L groups. Pulmonary hypertension induced by chronic hypoxia was markedly at-
tenuated after AT1 receptor blockade. SVR = systemic vascular resistance; P = placebo group; L = L-158,809 group; RA = room air. A 
significant decrease in the PVR/SVR ratio was observed during AT1 receptor blockade. Bars represent the mean ± SD value. *P < 0.05 
for significant difference between the P and L groups (repeated measures ANOVA).
Table 1. Effect of hypoxia and treatment with an angiotensin II type 1 blocker on 
newborn piglets.
Variables Group Normoxia  Chronic hypoxia
2 days 6 days
pH P 7.47 ± 0.03 7.51 ± 0.02 7.48 ± 0.04
L 7.41 ± 0.05 7.48 ± 0.04 7.50 ± 0.06
PaCO2 (mmHg) P 39 ± 6 30 ± 2 30 ± 4
L 42 ± 5 30 ± 2 31 ± 4
PaO2 (mmHg) P 94 ± 8 40 ± 9* 42 ± 7*
L 103 ± 8 47 ± 9* 45 ± 7*
BE (mM) P 5 ± 4 2 ± 2 1 ± 5
L 3 ± 5 1 ± 3 3 ± 4
Psa (mmHg) P 71 ± 6 78 ± 9 79 ± 16
L 75 ± 5 68 ± 6 70 ± 8
SVR (mmHg·L-1·min-1·kg-1) P 254 ± 26 234 ± 56 284 ± 89
L 299 ± 69 239 ± 31 263 ± 51
CO (L·min-1·kg-1) P 0.28 ± 0.03 0.32 ± 0.04 0.28 ± 0.07
L 0.24 ± 0.04 0.27 ± 0.02 0.25 ± 0.04
Data are reported as means ± SD. BE = base excess; Psa = mean systemic 
arterial pressure; SVR = systemic vascular resistance; CO = cardiac output; P 
= placebo group (N = 6); L = L-158,809 group (N = 7). There were no significant 
differences in arterial blood gas or acid-base values in room air/normoxia and 
hypoxia or in systemic hemodynamics and CO responses between groups. There 
was a statistically significant difference from normoxia to hypoxia in PaO2 values 
in both groups (*P < 0.05, Mann-Whitney U-test).
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Figure 2. Immunohistochemical localization of eNOS, iNOS, AT1-R and AT2-R in the lungs of the hypoxic groups L 
(L-158,809-treated) and P (placebo) that were submitted to 6 days of hypoxia and of normoxic piglets (group C, control). 
A-C, eNOS stained the endothelium of blood vessels (bv) in all groups; D-F, iNOS staining of the endothelium, alveolar 
and interstitial macrophages (ma) was observed in hypoxic (L and P groups) but not in normoxic animals; G-I, AT1-R was 
expressed in the endothelium of all groups; macrophages and type II pneumocytes (P II) were moderately stained in the 
groups L and P, and were weakly stained in normoxic (group C) animals; J-L, a weak AT2-R staining was observed in the 
endothelium (end), whereas macrophages in the P and L groups exhibited weak or moderate staining, respectively; M-P, 
immunohistochemistry controls for eNOS and iNOS were carried out omitting the respective primary antibodies (blank); 
controls for AT1-R and AT2-R were obtained by pre-adsorbing the primary antibodies with their respective peptide immu-
nogens; none of the controls were stained, indicating that detection was specific. Bars = 4 µm (A-F); 2 µm (G-L) and 10 
µm (M-P). eNOS = endothelial nitric oxide synthase; iNOS = inducible nitric oxide synthase, AT1-R = AT1 receptor; AT2-R 
= AT2 receptor.
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by anti-iNOS antibody, whereas that of the control group was 
essentially not stained (grade 0). Alveolar and interstitial mac-
rophages were detected in lower numbers and showed grade 
2 staining in the L group (Figure 2D) and grade 1 staining in 
the P group (Figure 2E), and this difference in macrophage 
staining was significant (P < 0.01). The control group (Figure 
2F) exhibited very few macrophages that stained grade 0 
(Table 2).
AT1-R immunostaining was detected in the endothelium 
and alveolar interstitium of all groups, with no statistically sig-
nificant differences among the three groups. Macrophages 
and type II pneumocytes were moderately stained in groups 
L and P, and were weakly stained in the C group (Figure 
2G-I; Table 2).
A mild AT2-R immunoreactivity was detected in the 
alveolar septa (grade 1) in all sections of the L group. Mac-
rophages of the P and L groups exhibited weak (grade 1) or 
moderate (grade 2) staining, respectively (Figure 2J,K). The 
P group significantly differed from the L group (P < 0.02), 
where only half the sections showed a weak macrophage 
staining for AT2-R expression (grade 1), and a weak staining 
in the endothelium and alveolar septa (Figure 2K). The C 
group showed a very weak or absent expression of AT2-R 
(Figure 2L). Immunohistochemical blanks showed no stain-
ing for any of the antibodies used (Figure 2M-P).
Western blotting of eNOS, iNOS and AT1 receptors
Hypoxia elicited a significant (P < 0.01) decrease of im-
munoreactive eNOS lung protein of both the P and L groups 
relative to the normoxia C group levels, as measured by 
immunoblotting (Figure 3A). Expression of iNOS protein did 
not significantly differ among the C, P and L groups (Figure 
3B). Although AT1-R expression in the L group was numeri-
cally smaller than in the C group (Figure 3C), the difference 
was not statistically significant. The P group significantly 
differed from the C group (P < 0.001), but not from the L 
group. These data are consistent with the interpretation of 
a tendency to down-regulation of AT1-R in the L group as 
compared to the normoxia C group.
Discussion 
Pulmonary hypertension induced by chronic hypoxia in 
newborn piglets was markedly attenuated by L-158,809, 
a highly potent and selective nonpeptide AT1-R blocker 
(19). The fact that the increase in the PVR/SVR ratio was 
significantly attenuated during chronic hypoxia in the L 
group suggests the occurrence of a selective pulmonary 
Figure 3. Western blot analysis of the expression of endothelial nitric oxide synthase (eNOS; Panel A), inducible nitric oxide synthase 
(iNOS; Panel B) and AT1 receptor (AT1-R; Panel C) in piglet lungs submitted (groups L and P) or not (group C) to 6 days of hypoxia. 
Data are reported as integrated optical density (IOD) per µg protein (mean ± SD), expressed in arbitrary units. C = control group; P = 
placebo group; L = L-158,809 group. *P < 0.01 compared to group C (one-way ANOVA and Tukey multiple comparison as a post hoc 
test).
Table 2. Immunohistochemical quantification by modal scores of eNOS, iNOS, AT1-R, and AT2-R. 
Structure eNOS iNOS AT1-R AT2-R
C P L C P L C P L C P L
Endothelium 3 2 2 0 1 1 1 2 2 1 1 1
Pneumo II 0 0 1 2 2 2 1 2 2 0 1 1
Macrophages 0 0 0 0  1*   2* 1 2 2 0 1** 2**
0 = not detectable, 1 = mild/weak, 2 = moderate, and 3 = strong staining. eNOS = endothelial nitric oxide synthase; iNOS = induc-
ible NOS; AT1-R = AT1 receptor; AT2-R = AT2 receptor; C = control group (N = 5); P = placebo group (N = 6); L = L-158,809 group 
(N = 7). There was a significant difference between the P and L groups for iNOS (*P < 0.01) and AT2-R (**P < 0.02) in macrophages 
(Mann-Whitney rank sum test). 
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vasodilatation after AT1-R blockade. 
The attenuation of the pulmonary hypertension of new-
born piglets exposed to hypoxia for 6 days is consistent with 
previous studies examining the role of the RAS during the 
development of chronic hypoxic pulmonary hypertension. 
Adult rats were exposed to 7 or 14 days of hypoxia, showing 
attenuation of pulmonary hypertension after AT1-R blockade 
(6,20). In another study using adult rats exposed for 2-6 
weeks to a 10% oxygen atmosphere in a normobaric cham-
ber, olmesartan medoxomil (an AT1-R blocker) significantly 
reduced the induction of hypoxic cor pulmonale not only on 
echocardiographic observations but also in brain natriuretic 
peptide, transforming growth factor β and endothelin gene 
expressions in molecular studies; systolic blood pressure 
was independent of olmesartan medoxomil (21). The same 
investigators reported that olmesartan still seems to block a 
potential positive feedback loop of the Ang II-AT1-R system, 
which may lead to attenuation of pro-inflammatory signals in 
the mouse lung, that are associated with hypoxic pulmonary 
hypertension (22). These observations were confirmed in 
adult humans when the RAS was not previously activated by 
dehydration or sodium depletion (23). In addition, we have 
demonstrated that pulmonary vasoconstriction induced by 
acute hypoxia in newborn piglets was significantly attenu-
ated by the AT1-R blocker losartan (2).
It is important to consider possible mechanisms underly-
ing pulmonary hypertension and the mechanisms related 
to the effects of the AT1-R antagonist, since hypoxic pul-
monary hypertension was attenuated by AT1-R blockade in 
the present study. The association between the exposure 
of newborn piglets to chronic hypoxia and impairment of 
the endothelium-dependent vasodilatation ability related 
to the decreased eNOS expression has been very well 
demonstrated (10). It should be pointed out that eNOS 
expression did not return to control values after 6 days of 
AT1-R blockade.
Concerning other sources of NO production, iNOS 
protein expression was not significantly different among 
groups in the present study. However, there was a statisti-
cally significant difference in iNOS immunohistochemical 
expression in modal macrophage scores. Probably this 
difference was not detected in terms of protein expres-
sion because the Western blot data were assessed in the 
whole lung homogenate, and the iNOS expression was 
only different between the P and L groups at the level of 
macrophages.
Inducible NOS, in contrast to eNOS, has been primarily 
related to the immune function of macrophages. Inducible 
NOS is induced by a variety of stimuli such as cytokines, 
inflammatory factors, and hypoxia, which result in the 
release of much higher amounts of NO by very complex 
mechanisms involving different modulating factors such as 
hypoxia-induced factor 1, interleukin 1-β and Ang II (24-27). 
However, in agreement with the data of the present study, 
some studies have shown that iNOS is up-regulated in the 
pulmonary vasculature and in cardiac tissue in different ani-
mal models and in humans exposed to hypoxia, suggesting 
that hypoxia down-regulates eNOS activity and expression 
and up-regulates iNOS. This may represent an alternative 
adaptive mechanism counteracting the effects of hypoxia 
in the cardiovascular system. This is not necessarily a 
favorable adaptive mechanism because excess iNOS can 
induce the production of reactive oxygen species such as 
nitrotyrosine, facilitating tissue damage and hypotension 
(26,28-30).
Concerning AT1-R protein expression, the present 
study did not show the transient up-regulation observed in 
rodents (6). On the contrary, only a down-regulation was 
demonstrable in the placebo group compared to normoxic 
controls. This could be related to species differences and the 
duration of hypoxia to which the animals were submitted.
Analyzing the mechanisms that could explain the ef-
fects of AT1-R blockade, several studies have shown that 
AT1-R blockade acts through increased NO production 
via the AT2-R, demonstrating the relationship between the 
RAS and nitrergic systems in different models, including 
the pulmonary circulation, causing vasodilatation (8,9,31-
33). Furthermore, increased Ang II can be converted to 
angiotensin-(1-7) by the action of angiotensin-converting 
enzyme-2. Angiotensin-(1-7) acts through the Mas recep-
tors (34,35) resulting in pulmonary vasodilatation and thus 
can counteract the action of Ang II, increasing the release 
of NO (36,37). 
The mild immunoreactive expression of AT2-R observed 
here in the P and L groups, significantly more intense in the 
L group, is unexpected during the neonatal period (6,38,39) 
and may represent a compensatory mechanism due to 
hypoxic pulmonary hypertension, perhaps enhanced by 
the AT1-R blockade in the L group.
In conclusion, pulmonary hypertension induced by 
chronic hypoxia was partially attenuated by AT1-R block-
ade in newborn piglets. The chronic hypoxic pulmonary 
hypertension could be explained by down-regulated eNOS 
expression. We suggest that AT1-R blockade attenuated 
the hypoxic pulmonary hypertension acting through AT2-R 
and/or Mas receptors and the nitrergic system in the lungs 
of hypoxemic newborn piglets.
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